



Monday 4th April

08:00 – 09:00 Meet the Expert sessions				
08:00 – 09:30	Location: Exchange Auditorium	Location: Exchange 8-10	Location: Exchange 11	Location: Charter 4
<p><b>Top abstracts with expert perspective: Lymphoma, CLL</b></p> <p><b>Chaired by Dr Kate Cwynarski and Dr Francesco Forconi</b></p> <p>BSH22-OR11 - Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study - Dr Graham Collins</p> <p>BSH22-OR12 - Sudden or Cardiac Deaths on Rituximab-Based Therapy were associated with a prior History of Hypertension or Cardiac Disease and the use of ACE-inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial - Dr Talha Munir</p> <p>BSH22-OR13 - Mosunetuzumab Monotherapy is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory Follicular Lymphoma who have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study - Dr Dima El-Sharkawi</p> <p>BSH22-OR14 - Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) - Dr Sridhar Chaganti</p> <p>BSH22-OR15 - CLL-VI: A UK study of vaccine responses in patients with B cell chronic lymphocytic leukaemia - Dr Helen Parry</p>	<p><b>Top abstracts with expert perspective-General Haematology including ITP &amp; Myeloproliferative Disorders</b></p> <p><b>Chaired by Dr Fenella Willis</b></p> <p>BSH22-OR16 - Bosutinib Versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia: Final 5-year Results From the BFORE Trial - Dr Dragana Milojkovic</p> <p>BSH22-OR17 - Efficacy and safety of avapritinib as first-line treatment of patients with advanced systemic mastocytosis: Results of EXPLORE and PATHFINDER clinical study - Dr Deepthi Radia</p> <p>BSH22-OR18 - Exploratory Analysis: Potential of pelabresib (CP-0610), a bromodomain and extraterminal domain inhibitor, as suggested by analysis of improvements in bone marrow histology and function in patients with myelofibrosis — preliminary data - Professor Claire Harrison</p> <p>BSH22-OR19 - Upfront Cytogenetic Studies for the work-up of thrombocytosis: are we overdoing it? - Dr Marylou Fenech</p> <p>BSH22-OR20 - Real world evidence from the UK ITP Registry on the effectiveness of the immunosuppressive therapies rituximab and mycophenolate mofetil in immune thrombocytopenia - Dr Vickie McDonald</p>	<p><b>Top abstracts with expert perspective: Red Cell Disorder</b></p> <p><b>Chaired by Dr Subarna Chakravorty</b></p> <p>BSH22-OR06 - Long-term Survival Benefit of Eculizumab Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria: Data From the International PNH Registry - Dr Morag Griffin</p> <p>BSH22-OR07 - Analysis Of Anemia Persistence And Related Adverse Events in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Pegcetacoplan - Professor David Dingli</p> <p>BSH22-OR08 - Genotype and Clinical Characterisation of HH disease in Malaysian patients - an Observational Multi-centres Study - Dr Sai Keat Tan</p> <p>BSH22-OR09 - Challenges of acute and chronic pain management in sickle cell disease: outcomes of an English national audit - Dr Sanne Lugthart</p> <p>BSH22-OR10 - Elavopivat, an investigational, once daily, sEH-inhibitor, improves sickle red blood cell health and survival in patients with sickle cell disease: an analysis of exploratory studies in a phase 1 trial - Dr Theodosia A. Kalfa</p>	<p><b>Top abstracts with expert perspective: ALL, AML MDS &amp; bone marrow failure &amp; Transplantation, gene &amp; cellular Immunotherapies</b></p> <p><b>Chaired by Professor Adele Fielding and Dr Richard Dillon</b></p> <p>BSH22-OR01 - Immunogenicity of Covid-19 vaccination in patients with myelodysplastic syndromes - Dr Jennifer Vidler</p> <p>BSH22-OR02 - CD9 derepression drives cellular differentiation and restores immune recognition in pediatric acute myeloid leukemia - Ms. Yaqun Xu</p> <p>BSH22-OR03 - Antibody responses to SARS-CoV-2 vaccination in patients with acute leukemia and high risk MDS on active anti-cancer therapies - Dr Wei Yee Chan</p> <p>BSH22-OR04 - Follow-up of Patients With FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia in the Phase 3 ADMIRAL Trial - Alexander E. Perl</p> <p>BSH22-OR05 - Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results - Dr Marcus Pereira</p>	
<p><b>The MacFarlane Biggs Lecture</b> <b>Chaired by Dr Nicola Mutch</b> <b>Location: Exchange Auditorium</b></p> <p>Professor Walter Ageno - Thrombosis in the splanchnic circulation</p>				
<p>09:30 – 10:15</p>				
<p>Location: Exchange Auditorium</p>				
<p><b>Difficult scenarios in the myeloproliferative spectrum</b> <b>Chaired by Professor Claire Harrison and Professor Adam Mead</b></p> <p>Professor Adam Mead - New understandings in blast phase MPN and implications for treatment</p> <p>Dr Dan Wiseman - Diagnosis and management of CMML</p> <p>Professor Ileana Jacques Kladjan - Management of young patients with MPN learnings from a European collaborative</p>				
<p>10:25 – 11:55</p>				
<p><b>Networking and lunch break</b> <b>Location: Central Hall and Exchange Hall</b></p>				
<p>11:55 – 12:55</p>				
<p>Location: Exchange Auditorium</p>				
<p><b>Education Committee session</b> <b>Chaired by Dr Andrew McGregor and Dr Suzy Morton</b></p> <p>Ms Ruth Evans</p> <p>Dr Fiona Miall</p> <p>Mr Osamah Ahmad</p> <p>Mr Paul Armitage</p>				
<p>12:55 – 13:55</p>				
<p><b>The Crucible Prize: What current haematology practices would seem absurd to the haematology community in 2050?</b> <b>Chaired by Dr Amy Cooper</b> <b>Judges: Rachel Brown, Muhammad Saif, Guy Pratt, Stavroula Chante and Mr Huw Rowswell</b></p> <p>Mr George Watkinson - Chemotherapy availability in an uncertain future</p> <p>Ms Jemima Miller - Time's up on single-use blood bottles: Discarding the idea of discarding our resources</p> <p>Dr Bala Bhaskar - Dependency of haematology patients on whole blood donors: A remote possibility by 2050</p> <p>Dr Richard Buka - 2050: A year of re-enlightenment?</p> <p>Mr Jamie Kok - Home is where the health is</p>				
<p>14:00 – 15:30</p>				
<p><b>Lymphoma SIG: Interpretation of the new DLBCL data from a UK perspective</b> <b>Chaired by Dr Wendy Osborne</b></p> <p>Professor Laurie Sehn - New approaches to front line treatment of DLBCL</p> <p>Professor Laurie Sehn and Professor Andy Davies - How will this impact UK practice?</p> <p>Professor Mehdi Hamadani - New approaches to treating filter patients with relapsed/refractory DLBCL</p> <p>Professor Mehdi Hamadani and Dr Sridhar Chaganti - How will this impact UK practice?</p> <p>Dr Pam McKay - Does the new data on CNS prophylaxis mean that we should change our UK approach?</p>				
<p>15:30 – 16:30</p>				
<p><b>Networking break</b> <b>Location: Central Hall and Exchange Hall</b></p>				
<p><b>Global Outreach in Haematology, perspectives from BSH and ASH</b> <b>Chaired by Professor Adele Fielding, President of BSH and Professor Jane Winter, President of ASH</b> <b>Location: Exchange Auditorium</b></p> <p>Professor Imelda Bates - Global outreach – haematology's past, present and future</p> <p>Professor Leslie Kean</p>				
<p>16:30 – 18:00</p>				
<p><b>Poster Session</b> <b>Location: Exchange Hall</b></p>				
<p>18:00 – 19:30</p>				

10:25 – 11:55	Location: Exchange 11	Location: Charter 4	Location: Central room 3-4
<p><b>Early Career Forum</b> <b>Chaired by Dr Mai Khalifa</b></p> <p>Mr Chris Bamber - How Physician Associates can contribute to your Haematology Department?</p> <p>Ms Jennifer Cooper - Things I wish people told me: tips and tricks for biomedical scientists</p> <p>Ms Gemma Whitehead - Things I wish people told me: tips and tricks for clinical nurse specialist</p>	<p><b>Industry Symposia</b></p> <p><b>Chaired by Professor Adele Fielding</b></p> <p>Professor Adele Fielding - General overview and outcomes for patients with B-ALL on UKALL14</p> <p>Dr Clare Rowntree - Outcomes for patients with T-ALL on UKALL14</p> <p>Professor Anthony Moorman - Novel genetic insights from UKALL14</p>	<p><b>Industry Symposia</b></p> <p><b>Chaired by Professor Charlie Craddock</b></p> <p>Professor Charlie Craddock - The 'TAP' experience of delivering early phase studies in blood cancer and the evolving plans to take this forward as a new model for academic-led trials delivery in UK blood cancer.</p> <p>Professor Jude Fitzgibbon - A perspective on opportunities for translational science in UK blood cancer trials</p> <p>Professor Simon Rule - An Industry perspective on the UK as a place to partner for drug development and opportunities for trial delivery/collaboration.</p>	<p><b>Diagnostic and treatment challenges for haematologic autoimmune disorders</b> <b>Chaired by Dr Nichola Cooper</b></p> <p>Dr Nichola Cooper - Will inhibition of specific pathways lead to better care in autoimmune haematological diseases? An update on SYK, BTK, FCγR and complement inhibition.</p> <p>Dr Charlotte Bradbury - First line therapy in ITP - how do we avoid steroids?</p> <p>Dr Taryn Youngstein - DADA2 deficiency in haematology</p>